trending Market Intelligence /marketintelligence/en/news-insights/trending/Y39SAAdeRYhHqJoQTAYA1Q2 content esgSubNav
In This List

US FDA approves expanded efficacy claim for Zimmer's knee pain drug

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


US FDA approves expanded efficacy claim for Zimmer's knee pain drug

The U.S. FDA approved an expanded 26-week efficacy claim for Zimmer Biomet Holdings Inc.'s Gel-One Cross-linked Hyaluronate for the treatment of knee pain associated with osteoarthritis.